Repligen Co. (NASDAQ:RGEN) Holdings Trimmed by Victory Capital Management Inc.

Victory Capital Management Inc. lessened its holdings in shares of Repligen Co. (NASDAQ:RGEN - Free Report) by 27.3% in the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 9,908 shares of the biotechnology company's stock after selling 3,716 shares during the quarter. Victory Capital Management Inc.'s holdings in Repligen were worth $1,426,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the business. Charles Schwab Investment Management Inc. boosted its holdings in Repligen by 4.0% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 377,900 shares of the biotechnology company's stock worth $54,395,000 after acquiring an additional 14,521 shares during the period. NBW Capital LLC boosted its holdings in Repligen by 19.7% in the 4th quarter. NBW Capital LLC now owns 25,194 shares of the biotechnology company's stock worth $3,626,000 after acquiring an additional 4,152 shares during the period. Norden Group LLC boosted its stake in shares of Repligen by 10.2% during the 4th quarter. Norden Group LLC now owns 3,698 shares of the biotechnology company's stock valued at $532,000 after buying an additional 341 shares during the last quarter. Smartleaf Asset Management LLC boosted its stake in shares of Repligen by 89.4% during the 4th quarter. Smartleaf Asset Management LLC now owns 1,057 shares of the biotechnology company's stock valued at $152,000 after buying an additional 499 shares during the last quarter. Finally, Nichols & Pratt Advisers LLP MA boosted its stake in shares of Repligen by 11.1% during the 4th quarter. Nichols & Pratt Advisers LLP MA now owns 1,505 shares of the biotechnology company's stock valued at $217,000 after buying an additional 150 shares during the last quarter. Institutional investors and hedge funds own 97.64% of the company's stock.

Remove Ads

Analyst Ratings Changes

Several equities analysts have recently commented on RGEN shares. Royal Bank of Canada increased their target price on Repligen from $203.00 to $205.00 and gave the company an "outperform" rating in a research note on Friday, February 21st. StockNews.com cut Repligen from a "hold" rating to a "sell" rating in a research note on Friday, February 21st. HC Wainwright reiterated a "buy" rating and set a $180.00 target price on shares of Repligen in a research note on Friday, February 21st. Evercore ISI began coverage on Repligen in a research note on Tuesday. They set an "in-line" rating and a $155.00 target price for the company. Finally, Canaccord Genuity Group began coverage on Repligen in a research note on Tuesday, December 17th. They set a "hold" rating and a $165.00 price objective on the stock. One analyst has rated the stock with a sell rating, six have given a hold rating and eight have assigned a buy rating to the company. Based on data from MarketBeat, Repligen has a consensus rating of "Hold" and a consensus target price of $178.64.

Repligen Stock Performance

NASDAQ RGEN traded up $0.68 during trading hours on Friday, hitting $140.02. The company had a trading volume of 623,142 shares, compared to its average volume of 650,573. Repligen Co. has a fifty-two week low of $113.50 and a fifty-two week high of $200.03. The company has a quick ratio of 8.76, a current ratio of 10.44 and a debt-to-equity ratio of 0.26. The business has a fifty day simple moving average of $156.18 and a 200-day simple moving average of $148.32. The firm has a market cap of $7.86 billion, a P/E ratio of -274.55, a price-to-earnings-growth ratio of 4.54 and a beta of 0.95.

Repligen (NASDAQ:RGEN - Get Free Report) last issued its earnings results on Thursday, February 20th. The biotechnology company reported $0.44 earnings per share for the quarter, topping the consensus estimate of $0.41 by $0.03. Repligen had a positive return on equity of 4.21% and a negative net margin of 4.64%. The firm had revenue of $167.55 million for the quarter, compared to analyst estimates of $167.58 million. Equities analysts predict that Repligen Co. will post 1.72 EPS for the current year.

Insiders Place Their Bets

In other Repligen news, Director Margaret Pax purchased 250 shares of the stock in a transaction dated Monday, March 17th. The shares were bought at an average cost of $150.69 per share, with a total value of $37,672.50. Following the completion of the acquisition, the director now owns 1,043 shares of the company's stock, valued at approximately $157,169.67. This trade represents a 31.53 % increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. 1.20% of the stock is owned by corporate insiders.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.